In Brief
Innate lymphoid cells (ILC) critically regulate tissue immunity and homeostasis in mice, but limited access to healthy human tissues has hindered efforts to profile anatomically-distinct ILCs in humans. Yudanin and colleagues provide a comprehensive map of the spatial and temporal dynamics regulating the anatomical distribution, subset heterogeneity, and functional potential of ILCs in non-diseased human tissues.
INTRODUCTION
Innate lymphoid cells (ILCs) are a recently recognized family of innate immune cells that have been implicated in playing critical roles in regulating immunity, inflammation, and tissue homeostasis in the context of infection, chronic inflammation, metabolic disease, and cancer (Brestoff et al., 2015; Chang et al., 2011; Eberl et al., 2015; Klose and Artis, 2016; Monticelli et al., 2011; Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Scandella et al., 2008; Sonnenberg et al., 2012 Sonnenberg et al., , 2013 .
Murine ILCs are defined by lack of expression of cell surface markers associated with granulocytes, dendritic cells (DCs), macrophages, and conventional B and T lymphocytes (termed Lineage negative, Lin À ) but can be positively identified by expression of CD127 (IL-7Ra), CD25 (IL-2Ra), and c-Kit (Buonocore et al., 2010; Colonna, 2009; Satoh-Takayama et al., 2010; Takatori et al., 2009; Vonarbourg et al., 2010) . Murine ILCs can be delineated into three categories: ILC1 populations that express T-bet and include classical NK (cNKs) cells and ILCs that express IFN-g (Diefenbach, 2015; Eberl et al., 2015; Klose and Artis, 2016; Mortha and Diefenbach, 2011) ; ILC2 populations comprised of IL-33 receptor (ST2)-positive cells that express the transcription factor GATA-3 and secrete the T helper-2 (Th2) cell-associated cytokines IL-5, IL-13, and growth factor amphiregulin (Almeida and Belz, 2016; Klose and Artis, 2016; Liang et al., 2011; Monticelli et al., 2011; Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Sonnenberg et al., 2013) ; and ILC3 populations that are IL-33R À , express RORgT, and produce the Th17 cell-associated cytokines IL-17A and IL-22 (Buonocore et al., 2010; Colonna, 2009; Satoh-Takayama et al., 2010; Takatori et al., 2009; Vonarbourg et al., 2010) . The majority of these effector cytokines have been shown to directly regulate epithelial and stromal cell responses at barrier surfaces, and many are predominantly secreted by ILC subsets enriched within these sites (Crosby and , from which four ILC populations (right) were isolated, sampling metabolic (Abd., abdominal; Mes., mesenteric), lymphoid (mLN, mesenteric lymph node; ldLN, lung-draining lymph node), and mucosal (LP, lamina propria; IEL, intra-epithelial lymphocytes) sites. Classical NK (legend continued on next page) Reynolds et al., 2010; Saetang and Sangkhathat, 2018; Sonnenberg et al., 2010) . In mice, anatomically-distinct ILC subsets critically provide robust tissue-specific protective responses against local pathogens and are functionally divergent in lymphoid versus mucosal sites (Klose and Artis, 2016; Mackay and Kallies, 2017, Ricardo-Gonzalez et al., 2018) . Tissue-resident murine ILC populations have also been implicated in promoting and sustaining chronic inflammatory diseases, including inflammatory bowel disease (IBD), allergic lung and skin inflammation, and obesityinduced immune dysregulation Lund et al., 2017; Saetang and Sangkhathat, 2018; Salimi et al., 2013) . Recent studies have identified human ILCs in fetal and adult inflamed or diseased tissues that phenotypically resemble murine ILC2 and ILC3 populations, suggesting they may also exhibit functional tissue specificity (Cella et al., 2009 (Cella et al., , 2010 Crellin et al., 2010; Cupedo et al., 2009; Li et al., 2018; Mjö sberg et al., 2011) . However, spatial distribution of ILCs is dissimilar between humans and mice, and may reflect differences in subset composition and/or function among anatomically diverse populations (Almeida and Belz, 2016; Simoni et al., 2016) . Importantly, limited access to non-diseased tissues has hindered efforts to understand how the tissue environment contributes to human ILC distribution, and whether anatomically-distinct subsets are preferentially compartmentalized within these sites remains unclear.
Here, we present a quantitative analysis of ILC distribution and heterogeneity in lymphoid, mucosal, and metabolic tissues obtained from a diverse cohort of 44 previously non-diseased organ donors over a wide range of ages and body mass indexes (BMIs). We combine phenotypic and transcriptional profiling of the major ILC subsets from 9 tissues with distribution variance and correlation analyses to identify distinctions in the temporal and spatial dynamics of human ILC populations. Our analyses reveal phenotypic and transcriptional diversity within and among anatomically-distinct human ILCs, which vary in the degree to which site-specific environmental cues impact their resultant distribution, phenotypic heterogeneity, transcriptional profile, and functional potential. Together, our results provide a comprehensive map of the spatial and temporal dynamics of human ILC populations in non-diseased tissues.
RESULTS
Human ILC Subsets Differentially Populate Anatomically Diverse Tissues ILC populations have been identified in numerous lymphoid and barrier sites where they provide tissue site-specific responses critical for both immune protection and tissue homeostasis. However, how the tissue environment contributes to ILC distribution, and whether specific ILC populations are preferentially compartmentalized within these sites remain poorly defined. While ILCs have been thoroughly characterized in mice, limited access to non-diseased human tissues has hindered efforts to interrogate the phenotype and function of anatomicallydistinct ILC populations in non-diseased humans. In an ongoing collaboration with LiveOnNY, we obtained access to multiple lymphoid, mucosal, and adipose tissues from previously nondiseased research-consented organ donors ( Figure 1A ). Specimens acquired from donors comprised nine tissues sampling major mucosal, lymphoid, and metabolic compartments (Figure 1A) . All donors were HIV-, HBV-, HCV-, cancer-free, and clear of systemic infection prior to brain death caused by head trauma (20.45%), anoxia (27.27%), stroke (50.00%), or other non-infectious traumas (2.27%) ( Figure 1B ). Comprising both obese and non-obese individuals over a broad spectrum of BMIs (mean BMI = 29) ( Figure 1B ), the 44 donors analyzed here ranged in age from 2 to 70 years (mean age = 46.2) (Figure 1C) and were predominantly male ( Figure 1D ). Additional descriptive statistics, CMV and EBV seropositivity, and individual attributes of each donor used in this study are compiled in Table S1 .
To Figure 1A , Table S2, Table S6 ). We designed a single-panel, surface marker-based flow cytometric identification strategy consistent with the standard in the field (Bernink et al., 2013; Bjö rklund et al., 2016; Lim et al., 2017; Simoni et al., 2016) , which allowed us to reliably and reproducibly distinguish these cell subsets across tissues while minimizing contamination from myeloid, T cell, and other cell lineages. Specifically, in all tissues we identified populations of CD56 + CD127 (Bernink et al., 2013; Bjö rklund et al., 2016; Lim et al., 2017; Simoni et al., 2016) (Figures 1E and 1F) .
To ensure gating stringency of ILCs and cNKs, we took several approaches. First, inclusion of CD5 was necessary to eliminate (cNK) (gray), ILC1 (red), ILC3 (green), and ILC2 (blue), subsets were further subdivided by expression of NKp44 and CD56 (ILC1 and ILC3) Table S1 , S2, and S3. See also Table S6 for a summary of donors and tissues used per figure panel. Representative flow cytometry histograms depict transcription factor expression by (B) lymphoid and mucosal ILC1, ILC3, and cNK or (C) lung-derived ILC1, ILC2, and ILC3 subsets from an individual donor.
(legend continued on next page)
T cell contamination (Lim et al., 2017; Simoni et al., 2016 Figure S1C ), although a small proportion of lung-specific cNKs can express CD16 ( Figure S1C ), and therefore we did not include this marker in our lineage gate. However, we found that inclusion of CD11b and CD11c in the lineage gate was essential to avoid substantial myeloid cell contamination, particularly in mucosal tissues. Critically, we found that in non-diseased human lymphoid and mucosal tissues, few of the CD127 + ILC subsets expressed CD11b or CD11c once contaminating myeloid cells were excluded. (Figures S1D-S1F ). Therefore, our stringent gating strategy was unlikely to be inadvertently excluding rare ILC populations from analysis. Collectively these data confirm the validity of our flow cytometric gating strategy as a robust, single-panel design for identifying human cNK and ILC subsets.
Spatial and Temporal Analyses Reveal Phenotypic
Heterogeneity within and among Human ILC Populations To discern whether ILCs in humans are compartmentalized within different tissues, we first analyzed the relative frequency of ILC subsets among nine mucosal, lymphoid, and metabolic tissues from 44 diverse donors. Composition and phenotypic heterogeneity was assessed within each tissue by flow cytometry, using markers established in mice ( Figures S2A and S2B ) and those used previously in limited human studies to delineate human ILC subsets and survey their expression of transcription factors (RORgT GATA3, EOMES, TBET), surface receptors (IL7Ra [CD127], CRTH2, NKp44) and maturation markers (c-Kit) ( Figure 1E, Figure 2 ). We found extensive heterogeneity in subset composition within human ILCs isolated from distinct tissue sites, with markedly different distribution patterns than murine ILC subsets (Figure 2A , Figure S2 ).
In mice, ILC2 and ILC3 were the major non-cNK subsets in tissues, with strict compartmentalization of ILC2s to epididymal (eWAT) and inguinal (iWAT) white adipose tissues and lungs, and ILC3 to intestinal sites ( Figures S2C and S2D ). In contrast, in humans, ILC1 and ILC3 subsets comprised the predominant non-cNK ILC populations in all tissues, and were proportionally more frequent at mucosal and lymphoid sites, particularly in the colon and ileum IEL, respectively (Figure 2A) . Analysis of transcription factor expression revealed that RORgT + ILC3s preferentially populated the spleen and LP jejunum ( Figure 2B ), while GATA3 expression was predominant in lung ILC2s ( Figure 2C ). Moreover, in the majority of individuals, ILC2 comprised a major non-cNK population within the lungs and metabolic tissues ( Figures S3C and S3D ). Although we identified both ILC2 and ILC3 in the human intestine ( Figure 2A ), the frequency of intestinal ILC2 varied widely among individuals (Figures S3E and S3F) and the ILC3 population potentially may also include progenitor cells, as described in a recent publication (Lim et al., 2017) . ILC1 and cNK subsets, which populated lymphoid and mucosal tissues, were heterogeneous in their expression of EOMES and TBET (Figure 2A, 2B, Figures S3G and S3H) . The proportion of ILCs within each tissue was consistent among diverse donors ( Figure S3 ), allowing us to statistically test whether fluctuations in subset frequency vary significantly (p < 0.05) as a function of tissue localization. To analyze differential ILC subset compartmentalization among lymphoid, mucosal, and adipose tissue sites, we quantified the cell numbers and mean subset frequency variance in each tissue ( Figure 2D , Table  S2 ). Although mucosal sites were preferentially populated by, and had significantly (p < 0.05) greater frequencies of ILC3s, the proportion of ILC1 and ILC3 cells in lymphoid tissues was similar ( Figure 2D , Table S2 ), suggesting that ILC subset distribution is less strictly compartmentalized in humans than in mice ( Figure S2E ).
Analyzing donors by age and BMI also enabled us to determine whether ILC subset composition varied with age or in metabolic disease. To assess quantitatively age and disease-dependent effects, we calculated the correlation between ILC subset frequencies within each tissue and donor age or BMI (Table S3 ). The impact of donor age or metabolic health on ILC subset composition differed among anatomically distinct populations. Intestinal ILC3 frequencies decreased with increasing age in a tissue-dependent manner, with a compensatory increase of intestinal cNK, while subsets in lymphoid tissue sites remained unchanged ( Figure 2E , Table S3 ). Conversely, increased donor BMI was correlated with a reduction in ILC1 and ILC2 frequencies within mucosal and abdominal adipose tissues ( Figure 2F , Table  S3 ). Together, these results indicate that tissue localization differentially impacts ILC distribution within human tissues in a subsetdependent manner.
(D) Distribution variance between subset frequencies was assessed for each tissue by two-way ANOVA with post hoc Holm-Sidak correction. Significant frequency variances between tissue pairs are indicated by p values, with red-and pink-shaded boxes (p < 0.001, red; p < 0.005, light red; p < 0.05, pink) and white boxes (ns). (E) Non-parametric spearman correlation analysis of changes in ILC subset tissue distribution with increasing age and (F) BMI is shown by tissue, ordered from adipose to lymphoid to mucosal sites. Correlation strength, directionality (r = À1, bottom to r = +1, top) and significance for each site is denoted by shading (p < 0.05, red; NS, not significant). For donor information and all individual values shown, see Table S1 , S2, and S3. See also Figure S2 for murine ILC distribution and Table S6 for a summary of donors and tissues used per figure panel. 
(legend continued on next page)
The human ILC subset-dependent effects of tissue localization, age, and disease on subset distribution prompted us to probe whether ILC subsets restricted within individual tissues are phenotypically and/or functionally distinct. Previous studies have reported that ILC subsets can vary in phenotype depending on activation state and/or tissue localization. We assessed NKp44 and CD56 expression on human ILCs isolated from nine tissues and found phenotypic heterogeneity within and among distinctly-localized subsets. In humans, expression of the cNK cell receptor, NKp44, was exhibited by ILC3s and intestinederived ILC1s ( Figure 3A , Crellin et al., 2010; Glatzer et al., 2013) . Additionally, these populations heterogeneously expressed CD56, a cNK cell receptor also marking activated T cells. Overall, spleen-and intestine-derived ILCs were more phenotypically heterogeneous than in lung and adipose, exhibiting greater variance in proportion of NKp44 + and CD56 + cells (Figures 3A and 3B, Figure S3 ). Expression of NKp44 was highest in mucosal ILC1 and ILC3 subsets and lowest in populations within lymphoid and metabolic tissue sites (Figures 3A and 3C) . This phenotypic heterogeneity exhibited by ILC1s and ILC3s was consistent, with little variation among donors ( Figure S3 ), and distinctly compartmentalized within each tissue ( Figure 3D) . Moreover, the impact of donor age and BMI differentially affected phenotypically distinct populations in a subset-dependent manner. Specifically, increasing age was associated with significant reductions (p < 0.05) in both NKp44 + and NKp44 À intestinal ILC3s, but had no impact on either population of ILC1s ( Figure 3E , Table S3 ). Conversely, obesity correlated with reduced proportions of NKp44 + but not NKp44 À ILCs in lymphoid and mucosal sites, although trends differed between IEL versus LP compartments of the SI and colon ( Figure 3F , Table S3 ). Moreover, we could also identify differences in ILC subset composition within anatomically related groups, as illustrated by altered frequencies of NKp44 + ILCs observed between two types of draining lymphoid tissue (ldLN versus mLN) in the context of age (ILC3s) or obesity (ILC1s) ( Figures 3E and 3F ). These results reveal distinct phenotypic heterogeneity within and among human ILC populations, with subset-specific effects in the context of age or obesity.
Tissue Localization Drives Transcriptional Heterogeneity in an ILC Subset-Dependent Manner Studies of murine ILCs have revealed that transcriptional differences among anatomically distinct subsets reflect tissuespecific heterogeneity in their function and protective capacity (Ricardo-Gonzalez et al., 2018) . To investigate whether differentially localized human ILCs are also transcriptionally distinct, we performed genome-wide analysis of sort-purified ILC1, ILC2, ILC3, and cNK subsets from jejunum, spleen, and lungs of 5 individual donors using high-throughput RNA sequencing.
Due to technical limitations of sequential, plate-based cell sorting, not all ILC populations could be isolated from every tissue. Despite this limitation, unbiased principal component analysis revealed tight clustering among ILC subsets regardless of localization, suggesting that the tissue environment is not the predominant determinant of transcriptional heterogeneity in human ILCs (Figure 4) . Furthermore, clustering was not distinct among samples from different donors ( Figures  S4A and S4B ). Of all ILC subsets, ILC3s were most transcriptionally distinct, overlapping least with other populations regardless of localization. Likewise, ILC2 samples clustered together with little overlap, although samples from the same tissue exhibited greater similarity. The least transcriptionally distinct population comprised ILC1s, which overlapped extensively with both splenic and intestinal cNK cells and shared some attributes with ILC3s ( Figures 4A and 4B ). ILC and cNK subsets in all tissues distinctly expressed transcription factors and surface markers previously established in delineating innate immune cell populations, including TBX21 (TBET), EOMES, KIT (CD117), RORC (RORgT), GATA3, ID2, IL7R (CD127), and NCR1 (NKp46) ( Figure 4C ). In concordance with previous studies (Bernink et al., 2013; Bjö rklund et al., 2016; Kr€ amer et al., 2017; Simoni et al., 2016) , and data from our phenotypic analyses ( Figure S3 ), we found that TBX21 and EOMES expression by cNK was heterogeneous and tissue-dependent. Specifically, TBX21 was expressed by all cNK ( Figure 4C ), although protein expression was highest among subsets within intestinal tissues ( Figure S3G ). While all cNK expressed EOMES transcriptionally ( Figure 4C ), protein expression was markedly higher in splenic and lymphoid cNK than in intestinal-derived cNK ( Figure S3H ). Among ILC subsets, TBX21 was predominantly enriched in ILC1, which also expressed EOMES heterogeneously ( Figure S3 , Figure 4C ). Conversely, neither ILC2 nor ILC3 expressed EOMES or TBX21 ( Figure 4C ). RORC expression was highest in ILC3 and not seen in ILC2, while GATA3 was expressed by both subsets ( Figure 4C ), as previously reported (Li et al., 2018; Mjö sberg et al., 2012) . Of note, while hierarchical clustering reflected similarly strong grouping by subset, ILC1s further formed small transcriptionally distinct cliques resembling either ILC2, ILC3, or cNK populations ( Figure 4C ). These findings were in contrast to results from murine studies in which fate mapping studies indicate that ILC1s comprise a lineage distinct from other helper-like ILC subsets (Diefenbach, 2015; Eberl et al., 2015; Klose and Artis, 2016; Mortha and Diefenbach, 2011) . Together, while these data validate our gating strategy to identify human ILC2 and ILC3, the heterogeneity in transcription factor expression among cNK and ILC1 ( Figure S3 ) suggests that delineation by canonical transcription factors alone may not accurately depict the complexity of these populations in diverse human tissue microenvironments.
(D) Distribution variance between ILC1 and ILC3 subset frequencies was assessed for each tissue by two-way ANOVA and adjusted for multiple comparisons using Holm-Sidak correction. Significant frequency variances between tissue pairs are indicated by p values, with red-and pink-shaded boxes (p < 0.001, red; p < 0.005, light red; p < 0.05, pink) and white boxes (ns). (E) Non-parametric spearman correlation analysis of changes in ILC1 and ILC3 subset tissue distribution with increasing age and (F) BMI is shown by tissue, ordered from adipose to lymphoid to mucosal sites. Correlation strength, directionality (r = À1, bottom to r = +1, top) and significance for each site is denoted by shading (p < 0.05, red; NS, not significant). For donor information and all individual values shown see Table S1 , S2, and S3. See also Figure S3 for distribution by donor, Table S6 for a summary of donors and tissues used per figure panel.
Subset-and Tissue-Specific Transcriptional Signatures Distinguish Mucosal Versus Lymphoid ILCs
The highly conserved, subset-specific gene signature exhibited by human ILCs suggests that subset identity, rather than tissue localization, may be a stronger determinant of ILC functional potential. Indeed, hierarchical clustering of subsets within spleen or jejunum clearly delineated cNK from ILC2 and ILC3 populations ( Figure S4C, Figures 5A and 5B). Overall, human ILC populations were transcriptionally distinct, particularly among ILC2, ILC3, and cNK cells, reflecting subset-specific functional potential that remained remarkably consistent between donors. Both splenic and intestinal cNK cells were enriched in genes related to host defense ( Figure 5C , Table S5 ), expressing a conserved network of cytotoxicity-associated transcripts including GNLY, GZMB, PRF1, GZMA, FASLG, IFNG, CD244, and SH2D1A ( Figure 5E ). Similarly, ILC3 subsets in both sites distinctly expressed a network of genes associated with responses to cytokine or lipid signaling, including IL7R, KIT, AQP3, PTGS2, and TNFRSF25 ( Figures 5D and 5F , Table S5 ). Compared to ILC3s or cNKs, we found that ILC2s had elevated expression of IL1R2, PTGS2, IL17RB, IL10RA, and CD74, genes that have been demonstrated to have in vivo significance in murine models (Stehle et al., 2016; Yu et al., 2016) (Figure S5A , Table S5 ). Moreover, subset-specific genes enriched in ILC2s encode markers that function in multiple pathways associated with type 2 immune responses, including IL13, IL1RL1, IL17RB, AREG, and CCR4 ( Figures S5B and S5C) (Izuhara, 2017; Schuijs and Halim, 2018; Zhou, 2012) . We also identified a number of genes that previously have not been associated with ILCs, such as PLAUR, PLIN2, SGK1, C5AR1, and IRAK3 ( Figure S5) Figure S4 for extended clustering, Table S1 for donor information, and Table S6 for a summary of donors and tissues used per figure panel.
to pursue targets and pathways of interest in human ILC development and function.
Our analyses revealed little distinction between spleen-and gut-derived ILC subsets, which were only distinct in expression of a few genes ( Figures S6A  and S6B) . However, these genes were similarly and consistently expressed by cNK and ILC3 populations within each site, suggesting an important role in tailoring tissue-specific functions ( Figures 5A and 5B ). Compared to intestinal cNK, splenic cNK had significantly (FDR < 0.1) increased expression of chemokine-and integrin-encoding genes, including CCL3, CCL4, and ITGB2, as well as activation and/or migration-related genes, such as S1PR5 and SELL (CD62L) ( Figures 5B and 5C, Figure S6A) . Similarly, jejunum-derived subsets upregulated known intestinal migration genes, including CCR9 and ITGAE ( Figures  5A and 5C , Figure S6B ). Tissue-specific distinctions predominantly comprised immune-associated transcripts downregulated in intestinal versus lymphoid tissues, such as IL1R1, RUNX2, and PCDH9 in ILC3s ( Figure 5D ) or FCGR3A, PRF1, and KLRC1 in cNK ( Figure 5C ). The global reduction of these transcripts within gut-derived ILC populations may be indicative of enhanced immune suppression at barrier sites with greater pathogen exposure, ostensibly to prevent unnecessary tissue damage.
Transcriptional Profiles of Anatomically-Distinct Human ILC1s Reflect Heterogeneity in Activation and Function
Growing interest in the potential plasticity of ILC subsets has resulted in particular focus on deciphering phenotypic and functional distinctions among ILCs, although the contribution of environmental cues to subset-specific characteristics remains unclear, particularly for populations within human tissues. Our results suggest that, although ILCs are less strictly compartmentalized in humans than in mice, localization differentially affects ILC population composition and distribution in a subset-dependent manner. Tissue-specific distinctions were particularly apparent Table S5 for tissue-and subset-specific signature genes, Table S1 for donor information, and Table S6 for a summary of donors and tissues used per figure panel. (C) Bar plots of log normalized counts (mean+SEM) depict select significant genes differentially expressed by cNK (gray) and ILC1 (red) populations within the spleen (striped) and jejunum (solid). Genes previously associated with particular ILC subsets are in bold.
(D) Violin plots of mean log normalized counts across subsets in all tissues show expression distribution of select subset-specific genes by ILC1s (red) and cNKs (gray).
(legend continued on next page)
for ILC1 populations, the distribution of which was significantly (p < 0.05) more affected by both local and systemic perturbations caused by obesity or aging. Furthermore, phenotypic and transcriptional heterogeneity varied widely among ILC1 subsets in lymphoid and mucosal sites, which resembled cNK and ILC3 populations, respectively ( Figure 4A , Figures 5A and 5B, Figure S4 ). Recent studies describe nearly indistinguishable ILC1 and cNK populations during inflammation (Bernink et al., 2013; Bjö rklund et al., 2016; Kr€ amer et al., 2017; Simoni et al., 2016; Cortez and Colonna, 2016) , revealing an increasingly multifaceted relationship between group 1 ILCs that is further highlighted by our findings, which suggest that anatomic localization provides additional layers of complexity. To investigate whether tissue site-specific environmental cues drive group 1 ILC heterogeneity, we analyzed the transcriptional profiles of cNK and ILC1 subsets isolated from mucosal and lymphoid compartments and found marked differences in population heterogeneity between distinctly localized subsets ( Figure 6 ). Specifically, gutderived ILC1s exhibited increased transcriptional heterogeneity compared to splenic ILC1s, as determined by hierarchical clustering of sample distances ( Figures 6A and 6B Figure 6A) , few of these genes distinguished ILC1 subsets across tissues ( Figures 6C and 6D) . Conversely, we found less transcriptional heterogeneity among splenic ILCs, which exhibited little distinction from co-localized cNKs ( Figures 6B and 6C) .
The lack of heterogeneity among ILC1 subsets in spleen may reflect their diminished functional capacity, their potential contamination by other ILC subsets due to a particular gating strategy, or indicate the presence of progenitor cell populations. To distinguish between these possibilities, we mined a previously published dataset (GSE60448) 
NKp46
+ cNK cells isolated from human umbilical cord blood (UCB), and compared significant transcriptional differences between these populations to those in our current dataset. Of the 74 significantly differentially expressed genes (sDEG; FDR < 0.1) between cNK and ILC1 subsets in our data, 22 were also sDEG between UCB-derived CLP and ILC1 populations (Figure 6E ). Among these, HLA-DOA, BCL11A, KIT, and IL7R were highly expressed by both ILC1 and CLP ( Figure 6E ). While KIT (CD117) and IL7R (CD127) are known markers of both CLP and ILC1 subsets (Vivier et al., 2018) , expression of BCL11A could be unique to lymphoid progenitors or progenitor-like cells. Future studies utilizing single-cell sequencing will be necessary to fully characterize heterogeneity within mature lymphoid and progenitor-like cell subsets.
DISCUSSION
While studies in mouse model systems indicate that ILCs serve as important regulators of immunity, inflammation, and tissue homeostasis in barrier sites (Brestoff et al., 2015; Chang et al., 2011; Eberl et al., 2015; Klose and Artis, 2016; Monticelli et al., 2011; Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Scandella et al., 2008; Sonnenberg et al., 2012 Sonnenberg et al., , 2013 , analysis of the phenotypic and functional characterization of human ILCs has been more limited. Recent studies have reported the existence of ILCs in some human fetal or diseased adult tissues (Mjö sberg et al., 2011; Mjö sberg and Spits 2016; Simoni et al., 2016; Brestoff et al., 2015; Monticelli et al., 2011; Cortez et al., 2017) . However, little is known about the composition of anatomically diverse ILC populations within healthy humans, and whether their site-specific heterogeneity reflects distinct responsiveness to host-, environmental-, or microbial-derived signals remains unclear.
Here, using a unique resource comprised of previously healthy organ donor tissues Granot et al., 2017; Kumar et al., 2017) , we have been able to comprehensively characterize ILCs across 9 tissues from 44 donors spanning over 50 years of life. Our data reveal differences in phenotypic heterogeneity both within and among human ILC subsets, with consistent expression patterns exhibited in each tissue. We found that although ILCs were less strictly compartmentalized in humans than in mice, localization differentially impacted population composition and distribution in an ILC subset-dependent manner. Our results support the possibility of distinctive effector functions among anatomically diverse ILC subsets, as human ILCs exhibit site-specific transcriptional signatures and responses to aging and metabolic disease.
While human and murine ILCs shared expression of some surface markers, there were enough distinctions and inconsistencies between them to raise fundamental questions about the biology of human ILCs (Klose and Artis, 2016; Mjö sberg and Spits, 2016; Montaldo et al., 2016; Simoni and Newell, 2018) . Murine ILC populations comprise three distinct subsets, whose functional capacities are tailored to the environments in which they reside (Ebbo et al., 2017 , Kim et al., 2016 , Klose and Artis, 2016 . Whether anatomically-distinct human ILCs are similarly affected by environmental signals has been difficult to examine due to limited tissue access. Our analysis of ILC subset distribution and phenotype across 9 lymphoid, mucosal and adipose tissues within an individual and across many donors revealed a more complex relationship between localization and heterogeneity than that in mice. ILCs in spleen and intestines were more phenotypically heterogeneous than those in lung and adipose, particularly in their expression of CD56 and NKp44. While NKp44 and CD56 have been noted on ILC3s and ILC1s, respectively, in previous publications using diseased tissues (Crellin et al., 2010; Glatzer et al., 2013) , our study examines how expression of these receptors changes with regard to tissue microenvironment in the context of healthy human tissues. overlapping transcripts. Heatmap shows relative expression of common genes in CLP and ILC1 cells, as indicated by row Z score ranging from low (black) to high (red). These and previously published sequencing datasets are, or will be made, publicly available on GEO (GSE60448). See Figure S6 and Table S5 for tissueand subset-specific signature genes, Table S1 for donor information, and Table S6 for a summary of donors and tissues used per figure panel.
Overall, our data illustrate that ILC1s are the most varied in phenotype. These results are consistent with a recent study of human ILC1s, which suggested that they may not be a homogeneous cell subset (Simoni et al., 2016) . Additionally, it is possible that current gating strategies for ILC1s, and to a lesser extent ILC3s, could potentially contain GATA3 + c-Kit +/À ILC2s that have downregulated CRTH2 upon entry into the tissue environment from the blood (Wojno et al., 2015) . Phenotypic differences between tissue-derived ILCs versus blood-derived ILCs are an important aspect of human ILC biology to consider for future studies.
To gain additional insight into the environmental impact on human ILC heterogeneity, we examined changes in subset composition among anatomically distinct sites within the donor population as a function of both age and BMI. Previous studies have relied on limited sample sizes and/or diseased human tissues, and have not been able to model changes over time or with health versus disease (Mjö sberg and Spits, 2016; Mjö sberg et al., 2011; Simoni et al., 2016) . Although directly probing tissuespecific responses of ILCs is not possible within the same individual, the wide range of BMIs and age represented by our donors, as well as the consistency of tissue subset composition among them, allowed an unprecedented quantitative analysis of the spatial and temporal dynamics of human ILCs in health and disease over life. However, given these are human samples from previously non-diseased, deceased donors, we cannot explore causation and can only infer potential correlations based on the data presented. Nevertheless, our approach revealed critical insights into the distinct impact of aging and tissue perturbation on anatomically diverse ILC populations. Results from these studies show that frequencies of intestinal, but not lymphoid, ILC3 decrease with increasing donor age. Moreover, NKp44 + ILC1 were reduced in obesity, with a compensatory increase in cNK populations. There could be numerous reasons for this selective increase in cNK cells (but not other ILC subsets) following the reduction of ILC1s. One explanation may be that because NKs are developmentally and functionally most similar to ILC1s compared to the other ILC subsets, NKs are more likely to take advantage of the cytokine milieu, including IL-15, to expand when there are fewer ILC1s to compete with for those signals in the tissue. Together, these data suggest that ILC subsets are differentially impacted by local signals, and in particular, implicate tissue localization in driving ILC1 heterogeneity.
Recent examination of human ILCs have begun probing whether these subsets transcriptionally resemble those in mice, as well as how their tissue-dependent transcriptional heterogeneity may influence resultant function (Bjö rklund et al., 2016; Mjö sberg and Spits, 2016; Sonnenberg et al., 2013) . Consistent with results from these studies, we found few tissue-specific differences among ILC subsets in spleen versus lymph nodes. Moreover, we observed no phenotypic distinctions between ILC2s and ILC3s among mucosal and lymphoid sites. In contrast, ILC1 populations were most transcriptionally diverse among tissues, with splenic ILC1 transcriptionally mirroring classical NK, while intestinal ILC1 more closely resembled ILC3 subsets. ILC1-like populations have been identified in intestinal epithelia, tonsils, skin, liver, and tumor infiltrates (Bernink et al., 2013 , and TBET expression in this population has been shown to be bi-modal (Mjö sberg and Spits, 2016) . Therefore the ''true'' ILC1 identity in nondiseased tissue remains controversial. The reduced heterogeneity and transcriptional similarity to CLP we observed among splenic ILC1 suggests that current definitions of this cell population may not sufficiently exclude progenitor-like cells. Full characterization of ILC1 heterogeneity necessitates the use of single-cell approaches sampling tissues across anatomic sites within an individual to truly distinguish ILC1 and cNK. To that end, findings detailed here are complemented and supported by results from a recent study (Crinier et al., 2018 ) using singlecell RNA sequencing (RNA-seq) to compare human and murine cNK signatures within spleen and blood. Of note, the spleenspecific cNK profiles described therein closely mirror our data from bulk RNA-seq of splenic cNK, both exhibiting tissue-specific expression of numerous genes, including KLRC1, PRF1, CCL3, IFNG, and ITGB2. Further, our RNA-seq analyses revealed that some ILC1s cluster more closely with ILC3s versus NKs in lymphoid versus intestinal tissues. Combined with the data in the recent study (Crinier et al., 2018) , these data provide a step forward in unraveling the complexity of ILC1 heterogeneity and relationship to the broader ILC family.
We demonstrate human ILCs widely vary in the degree to which site-specific environmental cues impact their resultant anatomic distribution, phenotypic heterogeneity, transcriptional profile, and functional capacity. By generating a comprehensive map of human ILC composition and spatial dynamics in non-diseased tissues over life, our results provide insights that cannot be inferred from previous studies limited to few anatomic sites, small sample sizes, or variable disease states of donors. We anticipate that these datasets will aid in revealing critical insights into the role of ILCs in promoting human health and tissue-specific pathologies.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: The spleen, mLN and lung-draining LNs were forcefully passed through a 70 mm filter and spun down. iWAT and eWAT were minced finely and placed in Collagenase II (Sigma Aldrich, St Louis, MO) at a concentration of 1 mg/mL for 1 hr. shaking at 37 C. After isolation, all cells were passed through a 70 mm cell strainer, spun down and any remaining red blood cells were lysed.
HUMAN LYMPHOCYTE ISOLATION
Spleen specimen were cleaned of fat and chopped into small pieces. The pieces were placed into 50 mL conical tubes with 10% FCS/RPMI Media, minced manually with scissors and were incubated by mechanical shaking at 37 C for 1 hr. After this incubation period it was forcefully passed through a stainless steel tissue sieve, subsequently through a 70 mm filter (Miltenyi, Bergisch-Gladbach) and pelleted through centrifugation. Centrifugation with Ficoll (GE Healthcare, Wauwatosa, Wisconsin) was used to separate lymphocytes. Residual red blood cells (RBC) were lysed using AKC lysis buffer, incubated for 5 min on ice and cells were washed with RPMI media. The surplus of cells recovered from all organs were frozen down in ice cold 90% DMSO+10% FCS.
For intestinal specimens, the fat was removed, the specimen was cut into small pieces and was cleaned with ice cold PBS by vigorous vortexing. The specimen was incubated in 1mM DTT (Sigma Aldrich, St Louis, MO) and 1 mM EDTA (Invitrogen, Grand Island, NY) for 1 hr, shaking at 37 C. The supernatant was collected, filtered through a 70 mm filter (Miltenyi, Bergisch-Gladbach), spun down and IELs were recovered by 40% Percoll. Enzymatic digestion media (collagenase D (Roche, Nutley, NJ) [2 mg/mL], trypsin inhibitor (life technologies, Carlsbad, CA) [1 mg/mL], and DNase I [0.1 mg/mL]), was injected submucosally into the intestinal samples and inflated tissues were kept at 37 C for 30 min after which tissues were minced manually with scissors and incubated shaking at 37 C for another 1 hr. After this incubation period the residual tissue was passed through a stainless steel tissue sieve, subsequently through a 70 mm filter (Miltenyi, Bergisch-Gladbach) and pelleted through centrifugation. The surplus of cells recovered from all organs were frozen down in ice cold 90% DMSO+10% FCS.
Lung tissues were minced manually into 50 mL conical tubes with scissors and specimen were incubated shaking at 37 C in enzymatic digestion media (as described above). After this incubation period the residual tissue was passed through a stainless steel tissue sieve, subsequently through a 70 mm filter (Miltenyi, Bergisch-Gladbach) and pelleted through centrifugation. Residual red blood cells (RBC) were lysed using AKC lysis buffer, incubated for 5 min on ice and cells were washed with RPMI media. The surplus of cells recovered from all organs were frozen down in ice cold 90% DMSO+10% FCS.
Mesenteric LN and lung-draining LN were minced finely and placed in collagenase D (Roche, Nutley, NJ) [2 mg/mL], trypsin inhibitor (life technologies, Carlsbad, CA) [1 mg/mL], and DNase I [0.1 mg/mL]) for 1 hr shaking at 37 C. After the digest the cell suspension was filtered through a 70 mm filter (Miltenyi, Bergisch-Gladbach) and pelleted through centrifugation. Residual red blood cells (RBC) were lysed using AKC lysis buffer, incubated for 5 min on ice and cells were washed with RPMI media. The surplus of cells recovered from all organs were frozen down in ice cold 90% DMSO+10% FCS.
Mesenteric and abdominal fat were cleared from as much connective tissue as possible, minced finely and placed in Collagenase II (Sigma Aldrich, St Louis, MO) at a concentration of 1 mg/mL for 1 hr shaking at 37 C. The obtained cell suspension was passed through a 70 mm filter (Miltenyi, Bergisch-Gladbach) and spun down. After centrifugation residual fat (floating on the top) was discarded and red blood cells (RBC) were lysed using AKC lysis buffer, incubated for 5 min on ice and cells were washed with RPMI media. The surplus of cells recovered from all organs were frozen down in ice cold 90% DMSO+10% FCS.
FLOW CYTOMETRIC ANALYSIS AND CELL SORTING
Murine and human cells were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (405 nm) (life technologies, Carlsbad, CA) for 20 min in PBS on ice, washed and consecutively stained with fluorophore-conjugated antibodies against surface markers. No pre-enrichment kits were used. For intracellular staining, cells were fixed and permeabilized utilizing a commercially available kit (eBioscience) and stained with fluorophore-conjugated monoclonal antibodies against transcription factors. After staining cells were washed and fixed in 2% paraformaldehyde (Bioworld, Dublin, OH) for flow cytometric analysis. For cell sorting, cells were kept on ice in 1% FCS in PBS with RNaseOUT Recombinant Ribonuclease Inhibitor (Life Technologies, Waltham, MA) and single, viable cells of interest were sorted using a BD Aria II. A complete list of antibodies used, as well as individual clone and source information, can be found in the Key Resources Table. RNaseq For each sample, 100 cells/well were sorted into TCL buffer (QIAGEN Germantown, MD,USA) in a Twin.tec PCR 96-well plate (Eppendorf; Hauppauge, NY, USA). Illumina SmartSeq2 RNA libraries were prepared by the Broad Institute, and paired-end sequencing was performed on an Illumina HiSeq at depth of 50M reads. Alignment and transcript counting was performed using STAR aligner and FeatureCounts. Linear dimensionality reduction and sample clustering were performed by principal component analysis (PCA). Because bulk RNaseq data is generated from pooled cells of a few individuals, PCA is generally preferred over non-linear clustering techniques, such as tSNE, which generate more distinct ''clusters'' and are often used for scRNaseq data. Normalized read counts and differential gene expressions were quantified using the R-based package DESeq2. Genes were defined as statistically significant at a nominal p value < 0.001 and a Benjamini-Hochberg adjusted FDR value of q < 0.1. Functional network and pathway analysis was performed for statistically significant differentially expressed genes using DAVID (NIAID, NIH), KEGG (Kanehisa Laboratories), and STRING 10.0 (SIB, CPR, EMBL).
Statistical analysis and visualization
All samples were acquired using BD Fortessa or BD LSRII (both BD Biosciences) and data were analyzed using FlowJo software (Tree Star Inc.). All statistical tests were selected with consideration to sample distribution and variance. Descriptive statistics (percent means, standard deviations, counts) were calculated for each cell subset and tissue in Microsoft Excel. Frequency variance was determined for each subset and tissue by Holm-Sidak post hoc correction for multiple comparisons following two-way ANOVA to exclude subset-dependent effects in GraphPad PRISM (Graphpad software, Inc., La Jolla, CA). Frequency comparison p values for each tissue versus each remaining tissue were graphed using Microsoft Excel. Correlation analysis of subset distribution versus age and BMI was calculated in GraphPad PRISM by nonparametric Spearman correlation for non-Gaussian distributions. Resulting two-tailed p values and R-values were graphed in Microsoft Excel and using GraphPad Prism. Tables  Table S2. Frequencies of ILC subsets in each tissue for each donor, related to Figure 2 and Figure 3 M-male, F-female; Abd. Fat-abdominal fat; LP-lamina propria; IEL-intraepithelial lymphocytes; Mes. Fat-mesenteric fat; ldLNlung-draining lymph nodes; mLN-mesenteric lymph nodes
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